全文获取类型
收费全文 | 170篇 |
免费 | 79篇 |
专业分类
林业 | 2篇 |
农学 | 2篇 |
1篇 | |
综合类 | 26篇 |
农作物 | 6篇 |
水产渔业 | 2篇 |
畜牧兽医 | 207篇 |
园艺 | 2篇 |
植物保护 | 1篇 |
出版年
2023年 | 12篇 |
2022年 | 3篇 |
2021年 | 4篇 |
2020年 | 12篇 |
2019年 | 16篇 |
2018年 | 20篇 |
2017年 | 31篇 |
2016年 | 18篇 |
2015年 | 12篇 |
2014年 | 14篇 |
2013年 | 11篇 |
2012年 | 8篇 |
2011年 | 8篇 |
2010年 | 13篇 |
2009年 | 8篇 |
2008年 | 6篇 |
2007年 | 7篇 |
2006年 | 6篇 |
2005年 | 4篇 |
2004年 | 4篇 |
2003年 | 5篇 |
2002年 | 3篇 |
2001年 | 4篇 |
2000年 | 4篇 |
1999年 | 2篇 |
1998年 | 3篇 |
1996年 | 2篇 |
1994年 | 1篇 |
1992年 | 1篇 |
1991年 | 1篇 |
1990年 | 1篇 |
1989年 | 2篇 |
1986年 | 1篇 |
1980年 | 2篇 |
排序方式: 共有249条查询结果,搜索用时 15 毫秒
71.
Rebhun RB Kent MS Borrofka SA Frazier S Skorupski K Rodriguez CO 《Veterinary and comparative oncology》2011,9(1):38-44
Dogs with multicentric T-cell lymphoma are commonly treated with CHOP chemotherapy protocols that include cyclophosphamide, doxorubicin, vincristine and prednisone. The purpose of this study was to evaluate the use of CHOP chemotherapy for dogs with multicentric T-cell lymphoma. Identification of prognostic factors in this specific subset of dogs was of secondary interest. Twenty-three out of 24 dogs responded to CHOP chemotherapy and these dogs remained on the protocol for a median of 146 days. No variable was associated with progression free survival (PFS) including stage, substage, hypercalcemia or radiographic evidence of a cranial mediastinal mass. The median overall survival time (OST) for all dogs was 235 days. Dogs that were thrombocytopenic at presentation experienced a significantly longer OST (323 versus 212 days, P=0.01). 相似文献
72.
The disposition kinetics and urinary excretion of gentamicin sulphate were studied in young buffalo bulls following a single intramuscular administration of the drug at 5 mg kg-1 body weight. The time course of the serum gentamicin concentration was adequately described by the one-compartment open model. The values of the absorption and elimination halflives were 12.2±2.2 and 167.0±29.7 min respectively. The apparent volume of distribution was 0.29±0.01 L kg-1. During the first 12 h, 63% of the total administered dose was excreted in urine. On the basis of the kinetic data, a satisfactory intramuscular dosage regimen for gentamicin sulphate would be at least 6 mg kg-1 body weight repeated at 8 h intervals. 相似文献
73.
T Osaki T Amaha Y Murahata Y Sunden A Iguchi K Harada K Tsujino K Murakami T Ishii K Takahashi M Ishizuka T Tanaka Y Okamoto 《Australian veterinary journal》2023,101(3):99-105
Malignant mesothelioma (MM) is uncommon in cats and dogs and can be challenging to diagnose. Adequate tissue sampling is required for superior diagnostic accuracy. Protoporphyrin IX, a metabolite of 5-aminolaevulinic acid (5-ALA), is a photosensitiser for photodynamic diagnosis (PDD). To the best of our knowledge, no study has reported the use of 5-ALA-PDD to detect MM in veterinary medicine. The present study describes the use of 5-ALA-PDD for MM diagnosis in a cat and dog, as well as the effectiveness of intracavitary chemotherapy. We evaluated the use of PDD with 5-ALA hydrochloride (5-ALA-PDD) in two cases of MM. A 12-year-old cat presented with a 1-month history of respiratory distress, and a 9-year-old dog presented with a 3-month history of mild abdominal distention. We endoscopically biopsied lesions in both the cases using 5-ALA-PDD. Histopathological examination revealed mesothelioma, and immunohistochemical staining was positive for calretinin. Both patients were treated with carboplatin. The cat died of respiratory failure. Although, the dog's condition improved 21 days after the first chemotherapeutic drug administration, the dog died on day 684 owing to cardiac-related issues. 5-ALA-PDD is thus, safe and feasible for the diagnosis of MM in veterinary medicine. 相似文献
74.
75.
C. M. Cannon M. C. Scott D. Ito B. H. Gorden A. J. Graef J. F. Modiano 《Veterinary and comparative oncology》2015,13(1):48-59
We evaluated the effect of Aurora kinase inhibitors AZD1152 and VX680 on canine osteosarcoma cells. Cytotoxicity was seen in all four cell lines; however, half‐maximal inhibitory concentrations were significantly higher than in human leukaemia and canine lymphoma cells. AZD1152 reduced Aurora kinase B phosphorylation, indicating resistance was not because of failure of target recognition. Efflux mediated by ABCB1 and ABCG2 transporters is one known mechanism of resistance against these drugs and verapamil enhanced AZD1152‐induced apoptosis; however, these transporters were only expressed by a small percentage of cells in each line and the effects of verapamil were modest, suggesting other mechanisms contribute to resistance. Our results indicate that canine osteosarcoma cells are resistant to Aurora kinase inhibitors and suggest that these compounds are unlikely to be useful as single agents for this disease. Further investigation of these resistance mechanisms and the potential utility of Aurora kinase inhibitors in multi‐agent protocols is warranted. 相似文献
76.
Aggressive local therapy combined with systemic chemotherapy provides long‐term control in grade II stage 2 canine mast cell tumour: 21 cases (1999–2012)
下载免费PDF全文
![点击此处可从《Veterinary and comparative oncology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
A. Lejeune K. Skorupski S. Frazier I. Vanhaezebrouck R. B. Rebhun C. M. Reilly C. O. Rodriguez Jr. 《Veterinary and comparative oncology》2015,13(3):267-280
This retrospective case series evaluates the outcome of 21 dogs with grade II stage 2 mast cell tumour (MCT) treated with adequate local therapy and adjuvant systemic chemotherapy (prednisone, vinblastine and CCNU). The median survival for all dogs was 1359 days (range, 188–2340). Median disease‐free interval was 2120 days (149–2325 days). Dogs treated with surgery and chemotherapy had shorter survival (median, 1103 days; 188–2010 days) than those that underwent surgery, radiation therapy and chemotherapy as part of their treatment (median, 2056 days; 300–2340 days). Two patients had local recurrence in the radiation field and four patients had de novo MCT. Distant metastasis was not observed in any dogs. The results of this study suggest that, in the presence of loco‐regional lymph node metastasis in grade II MCT, the use of prednisone, vinblastine and CCNU after adequate local‐regional therapy can provide a median survival in excess of 40 months. 相似文献
77.
DJ Batchelor SR Bright P Ibarrola S Tzannes L Blackwood 《New Zealand veterinary journal》2013,61(3):147-150
CASE HISTORY: A 6-year-old, entire male Flat-coated Retriever was presented with a history of lethargy, polydipsia and seizures. Clinical chemistry had shown marked azotaemia. CLINICAL FINDINGS AND DIAGNOSIS: Radiography and ultrasonography revealed bilateral renomegaly, and cytology of fine needle aspirates from the kidneys was diagnostic of malignant lymphoma. The dog was treated with a modified high-dose cyclophosphamide-, vincristine-, and prednisolone-based chemotherapy protocol, achieved remission, and returned to normal quality of life. Survival time was 346 days from the time of diagnosis. CLINICAL RELEVANCE: Malignant lymphoma in the kidneys of dogs has been considered to carry a uniformly poor prognosis. Long-term remission after medical treatment has not previously been reported. The favourable outcome in this case illustrates the limitations of clinical staging in determining the outcome for individual patients. 相似文献
78.
J. W. Elliott P. Cripps A. M. Marrington I. A. Grant L. Blackwood 《Veterinary and comparative oncology》2013,11(3):185-198
The aim of the study was to report the outcome of treatment of 97 dogs with lymphoma that received a multi‐agent chemotherapy protocol containing epirubicin as the primary anthracycline. Seventy‐five dogs received a 25‐week protocol with no maintenance phase whilst 22 dogs received a maintenance phase. Complete response rate was 96% and time to first relapse (TTR) and overall survival (OS) time for all dogs were 216 and 342 days, respectively. Dogs with T‐cell lymphoma and those classified as WHO substage b had significantly poorer OS times and TTR. The protocol was well tolerated with toxicity similar to doxorubicin‐containing protocols. Epirubicin as part of a multi‐agent protocol is safe and effective in the treatment of canine multicentric lymphoma. There is a high initial response rate and an overall median survival time that is similar to other published doxorubicin‐containing protocols. 相似文献
79.
Dose intense CHOP protocols have been shown to improve outcome for people with non‐Hodgkin's lymphoma, but evaluation of dose intense CHOP protocols for canine lymphoma is currently limited. The hypothesis of this retrospective study was that a 15‐week dose intense CHOP protocol would have shorter treatment duration with similar efficacy to other doxorubicin‐based multidrug protocols. Thirty‐one client owned dogs with multicentric lymphoma were treated with a 15‐week CHOP chemotherapy protocol with an overall response rate of 100% and a median progression‐free interval (PFI) of 140 days [95% confidence interval (CI) 91–335 days]. Dogs that had two or more treatment delays had significantly prolonged PFI and overall survival in multivariate analysis. Dose intensity did not correlate with patient outcome. Dogs experiencing multiple treatment delays secondary to adverse events may receive their individual maximally tolerated dose while dogs with no adverse events may be underdosed. Future studies should focus on individual patient dose optimization. 相似文献
80.
WANG Rui QIN Shu-kui CHEN Yu-qing WU Qiong YANG Yan LI Yu-mei WANG Zi-shu ZHENG Rong-sheng 《园艺学报》2013,29(3):436-441
AIM:To investigate the effects of combination of metronomic (MET) cyclophosphamide (CPA) with recombinant human endostatin (Endostar) as maintenance therapy on treating non-small-cell lung cancer (NSCLC). METHODS:The lung adenocarcinoma model of BALB/c nude mice was established by subcutaneous inoculation of A549 cells. Following 4 circles of CPA chemotherapy at maximum tolerated dose (MTD), the tumor-bearing mice were randomly divided into 4 groups:the mice in control group were treated with saline, the mice in MET CPA group were treated with CPA, the mice in Endo group were treated with Endostar, and the mice in MET CPA+Endo group were treated with CPA+Endostar. The volume of xenograft tumors and the survival rate of the mice were recorded. The circulating endothelial cells (CECs) and viable CECs in peripheral blood of tumor-bearing mice were detected by flow cytometry. The microvessel density (MVD) and pericyte coverage were observed by confocal microscopy. RESULTS: At the 6th week of maintenance therapy, the tumor volume in both MET CPA group and Endo group was significantly smaller than that in control group, and the highest inhibitory effect was observed in MET CPA+Endo group. The survival time of the mice in both MET CPA group and Endo group was significantly longer than that in control group, and the mice in MET CPA+Endo group showed the longest survival time. Compared with control group, MET CPA or Endostar significantly reduced the total number and viable CECs in peripheral blood of tumor-bearing mice and the MVD in the xenograft tumors. Endostar also considerably reduced pericyte coverage in xenograft tumors. MET CPA combined with Endostar even more greatly inhibited the angiogenesis-related indicators mentioned above. CONCLUSION:Combination of MET CPA with Endostar shows effective anti-tumor activity and leads to improved survival in a xenograft model of lung adenocarcinoma, which might be partly attributed to the enhanced anti-angiogenic effect of the combination therapy. 相似文献